Development and validation of a new method for potential use of Psoriasis Area and Severity Index in teledermatology

Australas J Dermatol. 2021 Feb;62(1):e114-e117. doi: 10.1111/ajd.13412. Epub 2020 Aug 16.

Authors

Jason Wu¹, Helmut Petto², Yves Dutronc³, Nicole Burkhardt⁴, Kurt Gebauer⁵, Melinda Gooderham⁶

Affiliations

¹ Toowong Dermatology, Toowong, Queensland, Australia.
² Eli Lilly Austria Pty Ltd, Vienna, Austria.
³ Eli Lilly and Company, Indianapolis, Indiana, USA.
⁴ Eli Lilly Australia Pty Ltd, Sydney, New South Wales, Australia.
⁵ Fremantle Dermatology, Fremantle, Western Australia, Australia.
⁶ Queens University and SKiN Centre for Dermatology, Peterborough, Canada.

No abstract available

Publication types

Letter
Validation Study

MeSH terms

Adult
Bioengineering / instrumentation
Body Surface Area
Dermatology / standards
Humans
Male
Psoriasis / pathology*
Severity of Illness Index*
Telemedicine / standards*